Standard Biotools Inc. (LAB): Capital Expenditures
$8.30M
Year ended 2025-12-31
$2.28M
Trailing 12 months to 2026-06-30
+29.5%
3-year compound annual growth
-8.2%
5-year compound annual growth
+7.6%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $8.30M | -0.6% | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | $8.36M | +195.1% | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | $2.83M | -26.0% | 2026-03-16, From 2023-01-01 |
| 2022-12-31 | $3.83M | -71.2% | 2025-03-11, From 2022-01-01 |
| 2021-12-31 | $13.26M | +4.3% | 2023-03-14, From 2021-01-01 |
| 2020-12-31 | $12.72M | +402.4% | 2022-03-08, From 2020-01-01 |
| 2019-12-31 | $2.53M | +580.4% | 2022-03-08, From 2019-01-01 |
| 2018-12-31 | $372.0K | -76.2% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $1.57M | -69.1% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $5.07M | +27.2% | 2019-03-18, From 2016-01-01 |
| 2015-12-31 | $3.98M | -46.2% | 2018-03-08, From 2015-01-01 |
| 2014-12-31 | $7.40M | +114.8% | 2017-03-03, From 2014-01-01 |
| 2013-12-31 | $3.45M | +44.5% | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | $2.38M | +42.2% | 2015-02-26, From 2012-01-01 |
| 2011-12-31 | $1.68M | +8.9% | 2014-03-12, From 2011-01-01 |
| 2010-12-31 | $1.54M | +92.6% | 2013-03-12, From 2010-01-01 |
| 2009-12-31 | $799.0K | n/a | 2012-03-26, From 2009-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Standard Biotools Inc. (LAB) | 2025-12-31 | $8.30M | -0.6% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $339.0K | -39.8% |
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $14.00M | +51.0% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $24.81M | +535.1% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $230.0K | -64.5% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $264.0K | -69.6% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $333.0K | n/m |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $220.0K | -29.0% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $42.77M | -45.4% |
Compare LAB, SPRY, NRIX, CYTK side by side · Screen every company in Pharmaceutical Preparations ↗